Monocacy Therapeutics Inc.

BiotechnologyBiotechnologyAIImmunology

📍 Monrovia, Maryland, United States• Founded 2025

StreetZero Signal 43

Be the first to signal interest

About Monocacy Therapeutics Inc.

Monocacy Therapeutics Inc. is a Frederick, Maryland biotechnology company focused on AI-guided immunology drug discovery and development. The company is developing first-in-class immune medicines guided by artificial intelligence to restore optimal immune function and health. It has reported multiple Form D filings including an unpriced SAFE offering with a first sale on May 5, 2026.

LATEST FUNDINGPrivate Placement

$49

Announced 2026-09-21

🔒

Unlock the full deal profile

Create a free account to see investors, key highlights, news, company details and the AI analysis for Monocacy Therapeutics Inc..

Create free account Sign in

Free plan includes 3 full deal profiles every month.

IN THE NEWS

EMPLOYEES—

FOUNDED2025

HQMonrovia, Maryland, United States

Industry

Biotechnology

Investors

TEDCO

Key highlights

Raised $114,450 via unpriced SAFE with two investors per SEC filing.
Listed total funding between $5K and $389K across tracking platforms.
Selected for FY26 Commercialization program by TEDCO and Maryland Business Innovation Association.
CIK 0002137361 registered in Monrovia, MD with founding year 2025.

Ask StreetZero about Monocacy Therapeutics Inc.

Put our AI to work on this deal.

What is Monocacy Therapeutics Inc.'s value proposition?Who are Monocacy Therapeutics Inc.'s competitors?Why does this raise matter?Summarize Monocacy Therapeutics Inc. for an investor.

Similar companies

Other Biotechnology deals, ranked by Signal.

Caspian Therapeutics, Inc.

$50.0M

Pictura Bio US, Inc.

$15.0M

Typewriter Therapeutics, Inc.

$56.3M

BioStem Technologies, Inc.

$40.0M

Source document & SEC filing

The source SEC filing and the cached document are available to members only. Sign in to view and download them.